Analyst Price Targets — PVLA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 7:33 pm | — | Truist Financial | $210.00 | $120.41 | TheFly | Palvella Therapeutics price target raised to $210 from $190 at Truist |
| February 24, 2026 6:49 pm | — | Chardan Capital | $210.00 | $118.61 | TheFly | Palvella Therapeutics price target raised to $210 from $174 at Chardan |
| February 24, 2026 4:25 pm | — | Stifel Nicolaus | $250.00 | $119.26 | TheFly | Palvella Therapeutics price target raised to $250 from $180 at Stifel |
| February 24, 2026 3:08 pm | — | H.C. Wainwright | $255.00 | $116.66 | TheFly | Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright |
| January 7, 2026 10:53 am | — | Mizuho Securities | $205.00 | $90.43 | TheFly | Palvella Therapeutics initiated with an Outperform at Mizuho |
| December 16, 2025 11:57 am | Whitney Ijem | Canaccord Genuity | $204.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $204 from $148 at Canaccord |
| December 16, 2025 11:54 am | Ryan Deschner | Raymond James | $193.00 | $91.51 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $193 at Raymond James |
| December 15, 2025 9:21 pm | — | Chardan Capital | $174.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $174 from $110 at Chardan |
| December 15, 2025 8:02 pm | Jeff Mukherjee | BTIG | $192.00 | $88.42 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $192 at BTIG |
| December 15, 2025 7:17 pm | — | Truist Financial | $190.00 | $88.89 | TheFly | Palvella Therapeutics price target raised to $190 from $105 at Truist |
Latest News for PVLA
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will…
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (Nasdaq: INCY) supporting the launch of OPZELURA®
Shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PVLA.
U.S. House Trading
No House trades found for PVLA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.